Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616606 | 0.79 | MAPT (0.41) | MEN1KMT2APARP1PNPACLY | |
| SCHEMBL3859120 | 0.79 | PARP1 (0.56) | MEN1KMT2APARP1PNPMAPT | |
| SCHEMBL7919209 | 0.77 | CTSS (0.42) | MEN1KMT2APARP1PNPMAPT | |
| SCHEMBL29804799 | 0.76 | MEN1 (0.44) | MEN1KMT2APARP1PNPMAPT | |
| SCHEMBL29804903 | 0.76 | MEN1 (0.44) | MEN1KMT2APARP1PNPMAPT | |
| SCHEMBL154615 | 0.76 | MEN1 (0.44) | MEN1KMT2APARP1PNPMAPT | |
| SCHEMBL1285346 | 0.76 | MEN1 (0.44) | MEN1KMT2APARP1PNPMAPT | |
| SCHEMBL12113051 | 0.76 | MEN1 (0.44) | MEN1KMT2APARP1PNPMAPT | |
| SCHEMBL13898339 | 0.76 | MEN1 (0.44) | MEN1KMT2APARP1PNPMAPT | |
| SCHEMBL7090535 | 0.76 | PNP (0.46) | MEN1KMT2APARP1PNPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088524-A1 | Compositions, Methods of Use, And Methods of Treatment | UNIVERSITY OF SOUTH FLORIDA | 2017-03-30 | — | — | US | disclosed |
| US-9556131-B2 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-01-31 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20140378516-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | UNIVERSITY OF SOUTH FLORIDA | 2014-12-25 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378516-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | LIPA, LCT, GAA | MEN1 2896/4885KMT2A 1425/4885PARP1 1285/4885 |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | MEN1 3339/4885KMT2A 4567/4885PARP1 1592/4885 |
| US-20170088524-A1 | Compositions, Methods of Use, And Methods of Treatment | LIPA, LCT, GAA | MEN1 2896/4885KMT2A 1425/4885PARP1 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.